(NASDAQ: ACLX) Arcellx's forecast annual revenue growth rate of 129.14% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 117.62%, and it is also forecast to beat the US market's average forecast revenue growth rate of 23.18%.
Arcellx's revenue in 2026 is $35,898,000.On average, 19 Wall Street analysts forecast ACLX's revenue for 2026 to be $7,918,842,183, with the lowest ACLX revenue forecast at $1,699,992,407, and the highest ACLX revenue forecast at $17,447,473,096. On average, 15 Wall Street analysts forecast ACLX's revenue for 2027 to be $14,276,466,850, with the lowest ACLX revenue forecast at $6,913,302,457, and the highest ACLX revenue forecast at $22,320,784,663.
In 2028, ACLX is forecast to generate $26,209,950,967 in revenue, with the lowest revenue forecast at $14,151,569,449 and the highest revenue forecast at $38,006,973,108.